( April 10, 2025, 11:14 AM EDT) -- WASHINGTON, D.C. — A Federal Circuit U.S. Court of Appeals panel affirmed a Delaware federal judge’s findings after a bench trial that a generic drug maker’s abbreviated new drug application (ANDA) did not infringe on a biopharmaceutical company’s patent related to a drinkable antibiotic treatment for a bacterial infection....